NASDAQ$AXSM
Axsome Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Axsome reported financial results for the second quarter ended June 30, 2021.
Axsome Therapeutics reported a net loss of $32.3 million, or $(0.86) per share, for the three months ended June 30, 2021. The FDA notified Axsome that they have identified deficiencies that preclude labeling discussions for AXS-05.
- FDA identified deficiencies that preclude labeling discussions for AXS-05
- NDA for AXS-07 for the acute treatment of migraine was submitted in the second quarter
- Phase 3 trial of AXS-12 for the treatment of narcolepsy is on track to initiate in the third quarter
- Completed a pre-NDA meeting with the FDA for AXS-14
Headline financials
Revenue & EPS history
Axsome · Revenue · Quarterly
$191M
Revenue by segment
Axsome · $57.8M total across 2 segments · Q3 2023
- AUVELITY$37.7M—65.2%
- SUNOSI$20.1M+19.6%34.8%
Forward guidance
Axsome believes that its cash at June 30, 2021, along with the remaining committed capital from the $225 million term loan facility, is sufficient to fund anticipated operations into at least 2024. Axsome expects that its operating expenses will increase year over year as they continue to build out the commercial function and further advance their pipeline.
Tailwinds
- Cash is sufficient to fund operations into at least 2024
- Remaining committed capital from the $225 million term loan facility will support operations
- Focus on commercial launch of AXS-05 in MDD
- Potential commercial launch of AXS-07 in migraine
- Advancement of pipeline
Headwinds
- Uncertainty regarding FDA approval of AXS-05
- Potential delays in AXS-05 approval due to identified deficiencies
- Increased operating expenses year over year
- Dependence on successful commercial launch of AXS-05 and AXS-07
- Potential impact of unforeseen circumstances or disruptions related to COVID-19
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-1.0%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+1.7%
Avg return
30 days after
51%
21 / 41 earnings
Positive
+12.9%
Q1 2022
Best reaction
-53.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.1% | +5.3% | +13.0% | |
| Q4 2025 | -4.7% | -10.8% | -11.9% | |
| Q3 2025 | +1.9% | +2.3% | +9.5% | |
| Q1 2025 | +3.7% | -4.0% | -3.6% | |
| Q4 2024 | -2.3% | +5.0% | -3.7% | |
| Q3 2024 | +7.5% | +2.4% | +3.7% | |
| Q2 2024 | +1.3% | -1.6% | +13.2% | |
| Q1 2024 | +2.9% | -3.1% | -0.9% | |
| Q4 2023 | -11.5% | -14.9% | -12.9% | |
| Q3 2023 | -3.1% | -11.9% | +6.5% | |
| Q2 2023 | -1.5% | -5.5% | +10.7% | |
| Q1 2023 | +4.1% | +7.1% | +2.4% | |
| Q4 2022 | +11.7% | +6.9% | +2.3% | |
| Q3 2022 | +11.2% | +3.4% | +36.9% | |
| Q2 2022 | +11.7% | +6.8% | +41.3% | |
| Q1 2022 | +12.9% | -6.1% | -24.3% | |
| Q4 2021 | +11.9% | +6.4% | +47.2% | |
| Q3 2021 | +1.4% | -2.3% | -12.6% | |
| Q2 2021 | -53.5% | -55.3% | -48.9% | |
| Q1 2021 | +0.1% | +2.6% | +11.5% | |
| Q4 2020 | +3.6% | -3.5% | -15.9% | |
| Q3 2020 | -9.7% | -6.3% | +7.1% | |
| Q2 2020 | -0.6% | +1.2% | -7.3% | |
| Q1 2020 | -2.8% | -7.9% | -15.7% | |
| Q4 2019 | -16.8% | -38.7% | -23.8% | |
| Q3 2019 | -1.2% | -4.6% | +76.4% | |
| Q2 2019 | +2.2% | +11.0% | -0.5% | |
| Q1 2019 | +7.2% | +10.7% | +12.2% | |
| Q4 2018 | +4.6% | +24.3% | +29.2% | |
| Q3 2018 | -15.8% | -28.1% | -24.7% | |
| Q2 2018 | -1.9% | -8.6% | +27.6% | |
| Q1 2018 | +1.5% | +3.0% | +4.5% | |
| Q4 2017 | +2.6% | +6.5% | -8.4% | |
| Q3 2017 | -4.1% | +1.0% | -0.5% | |
| Q2 2017 | -5.0% | -12.6% | -19.3% | |
| Q1 2017 | -1.2% | -1.2% | -4.8% | |
| Q4 2016 | -4.1% | +6.1% | -27.6% | |
| Q3 2016 | +0.7% | +4.1% | -17.8% | |
| Q2 2016 | -1.4% | -3.4% | -1.6% | |
| Q1 2016 | -1.4% | -3.4% | -1.6% | |
| Q4 2015 | -10.0% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro